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disease. The normal distribution of apoE genotypes in nephroticApolipoprotein E in idiopathic nephrotic syndrome and focal
patients with FSGS excludes a pathogenetic role of geneticsegmental glomerulosclerosis.
variants.Background. Hyperlipemia characterizes nephrotic syndrome
(NS) and contributes to the progression of the underlying ne-
phropathy. The data in the literature support an implication
of apolipoprotein E (apoE) in both hyperlipemia and focal
Severe hyperlipemia is a constant feature of nephroticsegmental glomerulosclerosis (FSGS), a malignant condition
associated with NS. syndrome, which is characterized by high cholesterol, tri-
Methods. The apoE genotype was determined in 209 ne- glyceride, and low-density lipoprotein (LDL) levels, while
phrotic patients, who were classified according to age and their the high-density fraction appears stable or only slightly
response to steroids as resistant children (N  96) and adults
decreased [1–3]. The predominant idea is that high cho-(43), and steroid dependent (33) and steroid responder (37) chil-
lesterol and LDL levels negatively influence the outcomedren. A total of 123 presented the histological features of FSGS.
In a subgroup of 28 patients, serum and urinary levels of apoE in these patients [4], but the mechanisms remain hypo-
and renal deposits were evaluated by immunofluorescence. thetical.
Results. The allelic frequencies of the three major haplo- Apolipoprotein E (apoE) is an amphipathic proteintypes ε2, ε3, and ε4 were the same in nephrotic patients versus
that plays an essential role in maintaining lipid homeosta-controls, and homozygosity for ε3ε3 was comparably the most
frequent genotype (70 vs. 71%) followed by ε3ε4, ε2ε3, ε2ε4, ε4ε4. sis brought about by the regulation of lipoprotein traffick-
Serum levels of apoE were fivefold higher in NS and in FSGS ing as well as cholesterol absorption and excretion [5, 6].
patients than in controls, with a direct correlation with hyper- A second major function of apoE is renal protection,cholesterolemia and proteinuria. ApoE genotypes did not in-
since it regulates mesangial cell proliferation and matrixfluence serum levels. Urinary levels were 1/10,000 of serum with
expansion [7]. It is not surprising that mice lacking apoEan increment in nephrotic urines. Finally, immunofluorescence
demonstrated the absence of apoE in sclerotic glomeruli, while for genetic manipulation develop atherosclerosis and re-
comparably nephrotic patients with membranous nephropathy nal lesions [8, 9] resembling glomerulosclerosis (FSGS).
had an increased glomerular expression of apoE.
Therefore, low apoE may affect the plasma lipid profile,Conclusions. ApoE is dysregulated in NS with a marked
while low glomerular apoE expression may affect mesan-increment in serum, which is a part of the complex lipid metabo-
lism. Down-regulation of glomerular apoE instead is a peculiar- gial cell proliferation and eventually be a determinant
ity of FSGS and may contribute to the pathogenesis of the of the accumulation of matrix.
Not all apoE isoforms possess these functions, how-
ever, since the rapid clearance of lipoproteins depends1 Drs. Bruschi and Catarsi contributed equally to this work.
on the presence of the Arg 158 residue, while a Cys in
Key words: hyperlipidemia, progressive renal disease, apoE genotype,
position 112 mediates binding to high-density lipoproteinlipid metabolism, cholesterol absorption, mesangial cell proliferation,
cell matrix. (HDL). ApoE3 is the unique subtype that carries both
amino acid residues and, therefore, the presence of ho-
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ies of a limited number of patients with FSGS indicate 2003 by the International Society of Nephrology
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Table 1. Clinical and pathological features in 209 children withan association of the two less frequent alleles ε2 and ε4 nephrotic syndrome who were enrolled for studying the
with FSGS [11, 12] or, more generally, with nephropa- apoE genotype
thies evolving to renal failure [13]. Moreover, the pres-
Steroid Steroid Steroidence of molecular variants of apoE, such as Sendai and/or resistants dependents responders
others, is associated with modifications of lipid composi- (N  139) (N  33) (N  37)
tion and glomerulosclerosis [14–18]. Sex M 82/F 57 M 17/F 16 M 26/F 11
Age at proteinuriaDespite the results of these background studies sup-
18 years 43 — —porting a role of apoE levels and/or variants in FSGS, no
18 years 96 33 37
data on apoE levels and renal expression are available. Sensitivity to Cys 19/58 17/19 10/10
Histology available 131 15 17Moreover, only very limited data on apoE genotypes in
FSGS 106 6 11glomerular disease and specifically in FSGS have been
Mes IgM 15 7 3
published. Both the quantity and the genotype of apoE MCN 10 1 3
could play important roles in the pathogenesis of FSGS, Patients were subdivided according to the response to steroids as resistant,
dependent or responder. Several patients of the three groups also were treatedsince the inhibitory effect on mesangial proliferation and
with cyclosporine with variable response. Most of the steroid resistant patientsmatrix production could be linked to the amount of presented the histology of FSGS (106), Mesangial IgM (15) and minimal change
nephropathy (10), but FSGS also was observed in the other groups. AbbreviationsapoE, while the presence of genetic variants may confer
are: CsA, cyclosporine; FSGS, focal segmental glomerulosclerosis; Mes IgM, mes-genetic predisposition to progressive glomerulopathies. angial proloiferating glomerulonephrites with IgM deposition; MCN, minimal
change nephropathy.The lack of data in this field is probably related to the
difficulty in routinely determining apoE levels in serum
and, for this reason, we developed a new technique for
determining apoE based on dot-blot and immunostain-
with pulse methylprednisolone (10 mg/kg, 6 cycles). Theing with specific anti-apoE monoclonal antibodies. The
relevant clinical (gender, age, age at onset of proteinuria,present study is aimed at evaluating the following points:
evolution toward renal failure) and pathological features(1) apoE genotype in a statistically significant population
are reported in Table 1, which shows a classification ofof children and adults with FSGS enrolled in Italy; (2)
the different groups according to steroid sensitivity: 139apoE levels in a cross-section of nephrotic patients, some
patients presented strict steroid resistance, 33 were ste-with histological evidence of FSGS, and association with
roid-dependent and 37 responded to one or more steroidgenotypes; (3) the relationship between apoE levels and
regimens. Forty-three of the corticoresistance cohortserum lipids and, finally, (4) the glomerular expression
were older than 18 years at onset of proteinuria, andof apoE with immunofluorescence. In the first approach
were considered as a separate group in the statisticalwe enrolled a sufficient number of patients to allow com-
analysis. Histology was available for 163 patients. Over-parison between children and adults with corticoresistant
all, 123 patients had a diagnosis of FSGS based on theNS, since they are actually considered different patholog-
presence of at least one segmental area of glomeruloscle-ical entities. For the quantitative approach, a cross-section
rosis in their biopsy, 25 presented mesangial IgM deposi-of the above patients with well-defined clinical character-
tion and 14 had no lesions. Most FSGS patients presentedistics was utilized, including patients with FSGS, and
persistent resistance to corticosteroids following the re-they were compared with other proteinuric pathologies
ported scheme, but cases of steroid-sensitive FSGS alsosuch as membranous nephropathy (MN). Finally, studies
were observed in the variant of frequent relapses ofon renal expression of apoE were performed in FSGS
proteinuria. The apoE genotype was evaluated also inpatients and for comparison in MN.
127 normal controls enrolled in our region plus 398 Ital-
ian subjects reported by another group [19].
METHODS
Patients for the apoE biochemical andPatients for apoE genotyping
immunopathologic studyThe patient population for the study of apoE geno-
Serum levels of apoE were determined in 60 patientstypes consisted of 209 children and adults with nephrotic
of the group described in the last section at differentsyndrome (Table 1), who had presented moderate to se-
stages of the disease and irrespective of the disease activ-vere proteinuria and had been treated with standard thera-
ity, which meant that for a few of them more than onepeutic protocols according to their sensitivity to different
serum sample could be checked. These patients weredrugs. The standard approach consisted of prednisone
utilized to define any correlation between serum levels(2 mg/kg for 30 to 60 days). In non-responders (partial
and genotypes and/or with proteinuria. In a cross-sectionor global) steroids were associated or substituted with
of the patients, serum and urine were obtained at diseasecylophosphamide (2 mg/kg for 60 days) or with cyclospo-
onset or at recurrence, which then were utilized for bio-rine (5 mg/kg starting dose, followed by tapering). Pa-
tients with steroid-cyclosporine resistance were treated chemical analysis (Table 2). They comprised 28 children,
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Table 2. Clinical features and laboratory data of 20 children with idiopathic nephrotic syndrome and 8 with FSGS
Age at Serum Serum
Age onset Creatinine cholesterol triglycerides
Patient Proteinuria Serum ApoE
number Sex g/day lg/mL Therapiesyears mg/dL
Idiopathic nephrotic syndrome
1 M 8 6.5 15.0 593.09 0.4 218 119 Pred, statins
2 M 7 5.5 2.0 74.83 0.3 263 98 Pred, CsA, statins
3 M 6 4.5 3.9 238.88 0.3 327 330 Pred, statins
4 M 8 7 2.5 130.18 0.3 114 236 Pred, statins
5 M 10 8 1.0 68.03 0.9 170 170 Nothing
6 F 4 3 30.6 408.06 0.4 114 46 Pred, statins
7 F 3 1.5 10.0 903.62 0.5 492 369 Pred, CsA, statins
8 M 4 3 0.9 116.70 0.4 449 220 Pred, statins
9 M 9 7 6.9 109.41 0.4 314 176 Pred, statins
10 M 7 2 1.0 342.26 0.5 269 106 Pred, statins
11 M 9 4.5 1.7 116.70 0.5 229 162 Pred, statins
12 M 5 3 3.0 210.36 0.3 309 60 Pred, statins
13 F 8 7 10.0 486.58 0.7 491 46 Pred, statins
14 M 4 3.5 1.3 103.98 0.4 273 68 Pred, statins
15 M 5 4 7.8 85.45 0.4 456 374 CsA, statins
16 M 9 8 10.0 223.51 0.7 369 412 Pred, CsA, statins
17 F 5 3.5 2.0 38.30 0.3 180 110 Pred, statins
18 F 7 6.5 5.0 497.25 0.4 425 209 Pred, statins
19 M 6 5 4.0 148.00 1.1 142 108 Pred, statins
20 F 14 12 4.0 342.87 466 121 Pred, statins
FSGS with protenuria
21 F 6 4 13.0 137.42 0.7 459 540 Pred, CsA, ACE I
22 M 16 8 1.0 626.73 0.9 137 59 Pred
23 M 16 8 2.4 73.07 0.9 170 77 Pred
24 F 11 4 8.2 141.81 7.0 119 517 ACE I
25 M 6 3 14.0 78.21 0.7 325 305 Pred, ACE I
26 M 15 2 3.8 223.85 1.0 236 114 Pred, CsA
27 M 17 8 3.8 113.85 1.1 178 116 Pred, CsA, ACE I
28 M 16 7 1.2 45.91 2.6 192 176 ACE I
Children with idiopathic NS were presenting proteinuria at the time of the enrollment, but after they underwent remission after a regimen with steroids and CsA
(Methods section). Patients with FSGS presented strict resistance to both drugs and underwent a renal biopsy for diagnostic purpose. Abbreviations are: Pred,
prednisone; CsA, cyclosporine; ACE I, angiotensin-converting enzyme inhibitor.
20 with idiopathic NS, that is, acute proteinuria and sensi- Serum, urine and DNA
tivity to steroids or to cyclosporine in most cases, and 8 Sera for apoE measurement were obtained in the
with FSGS; for clinical reasons, the diagnostic approach morning after an overnight fast, and in parallel a blood
in patients the former group did not include a renal sample was collected in ethylenediaminetetraacetic acid
biopsy. Eight patients presented strict resistance to ste- (EDTA) for DNA purification. Serum was centrifuged
roids and cyclosporine at the doses described earlier, at 1500  g for 15 minutes and then stored at 80C.
and for this reason they underwent a renal biopsy that On the same day, the first morning urine was collected
in all cases demonstrated lesions typical of FSGS (at in sterile vials, and after centrifugation at 8000  g for
least one area of segmental or global glomerulosclerosis).
10 minutes the supernatants were stored at20C. DNA
The gap between actual age and age at onset was differ-
was extracted by affinity column (Boehringer Mannheiment between groups, because the time lag between onset
GmbH, Mannheim, Germany).of proteinuria and follow-up was brief in the former
group. All the patients enrolled in this study group were ApoE genotyping
treated or had been treated in the previous six months
Apolipoprotein E genotypes were determined by mul-with steroids associated in some cases with cyclosporine
tiplex amplification refractory mutation system-polymer-and angiotensin converting enzyme (ACE) inhibitors.
ase chain reaction (ARMS-PCR) as described by Do-Most were treated with 3-hydroxy-3-mathylglutaryl coen-
nohoe et al [20], modified by the use of Perkin Elmerzyme A (HMG CoA) reductase inhibitors. Finally, 22
Taq-Gold (1 U with related buffer) and different magne-patients with NS and renal histological lesions of mem-
sium chloride and primer concentrations. Accordingly,branous nephropathy (aged between 18 and 60 years)
for detecting Arg 112 and Arg 158, we used 1.8 mmol/Lwere enrolled for evaluating the importance of NS in
of MgCl2; for Arg 112 and Arg 158, the allele specific-the regulation of serum apoE. Serum and urine were
primer concentration was 0.6 mol/L. For detecting Cysobtained also from 50 age-paired normal controls to de-
fine the reference range of apoE levels in Italy. 112 and Cys 158, 1.5 mol/L of MgCl2 was used, and
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the concentration of the allele-specific primer was 0.4 Determination of apoE in serum and urine
mol/L for Cys 112, and 0.8 mol/L for Cys 158. In all All samples and the calibrator serum were diluted
reactions the same 0.8 mol/L common primer and 32 with TBS pH 7.4 (1:10 vol/vol). A calibration curve was
nmol/L -1-antitrypsin primer concentrations were uti- prepared by dilution of purified apoE in TBS at the pro-
lized. Amplification was performed with a Genenco grammed levels of 25, 50, 100, 200, 400 and 800 g/mL.
Thermocycler (Model PTC 200). Sera and urines were diluted in the same buffer to achieve
the desired range of levels, within the standard curves.
Antibodies For apoE determination we utilized a Bio-Dot appara-
Monoclonal anti-apoE antibodies (clone 2E1) were tus (Bio-Rad, Hercules, CA, USA) following the instruc-
tion manual with minor modifications. Accordingly, theobtained from Roche (Mannheim, Germany). Their speci-
nitrocellulose membrane was pre-wetted in TBS andficity for apoE was evaluated by immunoWestern blot
placed on a sheet of Whatman 3MM filter paper soakedafter two-dimensional electrophoresis of whole serum
in the same solution. After removal by gentle pressure(Fig. 1), the methodology of which has previously been
of the air bubbles trapped between the two sheets, thedescribed in detail [21]. Briefly, the IPG strips were rehy-
sample template was placed on the nitrocellulose mem-drated overnight at 4C in 9 mol/L urea, 2% wt/vol
brane and a vacuum was applied for a few minutes, to fillCHAPS; 0.6% wt/vol carrier ampholytes with a wide
up the 96 sample wells with 50 L using a multichannelrange mixture (60% pH 4 to 8, 40% pH 3.5 to 10) and
pipette. The vacuum was applied until all of the samplesa trace of bromophenol blue. Proteins, 30 g, were solu-
were adsorbed. The same operation was repeated fivebilized with a solution containing 9 mol/L urea, 4% wt/
times with 150 L of buffer each, to wash out the non-vol CHAPS and 40 mmol/L Tris. Isoelectric focusing was
adsorbed sample. The nitrocellulose then was removedperformed at 18C. The pH gradient was created with
gently.Immobilines (IPGs; Amersham Pharmacia Biotechnical,
Hybridization was preceded by incubation with aAmsterdam, The Netherlands) pH between 3 and 10 in
blocking solution of 0.5% polyvinyl-pyrrolidone mixturethe first dimension; sodium dodecyl sulfate-polyacryl-
(10,000 and 40,000 molecular weight) in 0.1 mol/L aceticamide gel electrophoresis (SDS-PAGE) in the second
acid for one hour at 37C, which then was removed bydimension was performed following the original tech-
washing in 20% Tween-TBS. Incubation with the horse-nique described by Bjellqvist et al [22]. The applied volt-
radish peroxidase (HPR)-anti-apoE antibodies complexage for electrophoresis was increased from 300 to 3500 V
0.5 g/mL in 1% bovine serum albumin (BSA) in TBSduring the first five hours, followed by 5000 V for a total
was done for two hours at room temperature.of 100 kV h. Before the two dimensional (2-D) run,
The membrane was then washed with TBT-T fourIPG strips were equilibrated within the strip tray for 30
times, 15 minutes each, prior to developing the immu-minutes with a solution of 0.05 mol/L Tris-HCl buffer
noblot with the enhanced chemifluorescence reagent
pH 6.8, 6 mol/L urea, 30% vol/vol glycerol, 2% wt/vol
ECL-Plus kit (Amersham Pharmacia Biotech). The de-
SDS and a trace of bromophenol blue. The second di-
tection of fluorescent signals was acquired with the Opti-
mension was performed on 180  160  1.5 mm slabs of cal Scanner Storm 860 with an excitation of 	 420 nm
polyacrylamide gradient gels (%T 8-16) using piperazine and emission of 	 460 nm.
diacrylamide (PDA) as cross-linking agent. The gels Validation of the assay was done by determining apoE
were run at 45 mA/gel constant current and maintained levels in a standard and in three normal sera at different
at a temperature of 12C. dilutions (Fig. 2). Coefficients of variation were calcu-
For the Western blot, proteins were transblotted to lated by repeating apoE determinations at five different
Hybond nitrocellulose membranes (Amersham Phar- dilutions in ten sera.
macia Biotech) with a Novablot semidry system using a
continuous buffer system with 38 mmol/L Tris, 39 mmol/L Immunofluorescence
glycine, 0.035% SDS and 20% methanol. The transfer Apolipoprotein E expression in the kidney was studied
was achieved at 1.55 mA/cm2 for 3.5 hours. by indirect immunofluorescence in renal biopsies of 12
patients with FSGS, 6 with MN and, for comparison, in
Preparation of antibody-enzyme conjugate 12 cadaver kidneys that could not be grafted because of
Two hundred micrograms of the monoclonal apoE vascular abnormalities.
antibodies were coupled to horseradish-peroxidase (HPR) Tissue samples for light microscopy were fixed in 4%
(EC 1829696) according to specific information given by buffered paraformaldehyde and embedded in paraffin.
the peroxidase labeling kit (Roche, Mannheim, Germany). Routine stainings were performed according to standard
The conjugate was mixed with an equal volume of glyc- techniques. For immunofluorescence, the unfixed renal
tissue was embedded in OCT compound (Miles Scien-erol for storage at 20C.
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Table 3. ApoE genotype and allele frequency in a group of 209 nephrotic children who were subdivided according to the
clinical response to steroids
Nephrotic syndrome N (%)
Normals Overall Steroid-sensitive Steroid-dependent Steroid-resistant Steroid-resistant
(N  525) (N  209) (N  37) (N  33) 18 years (N  92) 18 years (N  43)
ε2ε2 5 (1) 0 0 0 0 0
ε2ε3 44 (8) 23 (11) 2 (5.4) 4 (12.1) 13 (14.1) 4 (9.3)
ε2ε4 10 (2) 6 (2.9) 0 1 (3.1) 3 (3.1) 1 (2.3)
ε3ε3 372 (71) 146 (70) 28 (75.7) 23 (69.7) 67 (72.7) 28 (65.1)
ε3ε4 9 (17) 33 (15.6) 6 (16.2) 4 (12.1) 13 (14.1) 10 (23.3)
ε4ε4 4 (1) 1 (0.5) 1 (2.7) 0 0 0
Allelic frequency
E2 6% 6.9% 2.7% 9.1% 8.3% 5.8%
E3 84% 83.3% 86.5% 81.8% 83.3% 81.4%
E4 10% 9.8% 10.8% 9.1% 8.3% 12.8%
Our controls consisted of 127 normal people enrolled in our region, plus 398 normal controls from Italy reported in another work [19].
tific, Naperville, IL, USA), snap-frozen in a mixture of of the disease in the proteinuric population, but it was
determined by the necessity to look for an associationisopentane and dry-ice and stored at 80C. Subse-
quently, 5 m sections were placed on slides and stored between apoE genotypes and glomerulosclerosis, more
than between apoE and proteinuria. The group of pa-at 20C until being immunostained.
Briefly, cryosections were fixed in cold acetone, rinsed, tients with corticoresistance actually consisted of 96 chil-
dren and 43 adults (Table 1) who were considered sepa-and sequentially incubated with the primary rabbit poly-
rately for statistical analysis, since corticoresistance and/clonal antibody against apoE, followed by fluorescein
or FSGS occurring in children and adults is not consid-isothiocyanate (FITC)-labeled goat anti-rabbit second-
ered unequivocally the same disease. Renal histologyary antibody (Zymed, Histoline, Milan, Italy). After wash-
was available in 131 cases, demonstrating FSGS in 106,ing, sections were then mounted with an anti-fading mount-
mesangial proliferation with IgM deposits in 15, anding medium (Vectashield; Vector, DBA Italia SRL, Milan,
minimal lesions in 10. This is in agreement with theItaly). Specificity of labeling was demonstrated by the
concept that renal histology is variable in these subjectslack of staining after substituting phosphate-buffered sa-
depending on sampling problems, and does not corre-line (PBS) and proper control immunoglobulins (Zymed)
spond to clinical outcome. The frequency of the threefor the primary antibody.
most common apoE alleles—ε2, ε3 and ε4—together with
Statistical methods the percentage of homozygous and heterozygous carriers
of the different haplotypes are reported in Table 3, whichSerum concentrations of apoE in patients with idio-
shows the frequencies for every separate group and forpathic nephrotic syndrome and FSGS versus controls
age. Overall, the allelic frequencies for the apo ε2, ε3 andwere compared utilizing one-way analysis of variance
ε4 haplotypes in nephrotic patients were 6.9%, 83.3%(ANOVA). The frequency of different apoE haplotypes
and 9.8%, respectively, which were very similar to thein controls and in our cohorts with nephrotic syndrome
frequencies in a normal population of 525 Italian subjects.was compared with chi-square analysis. Data are ex-
Homozygous carriers of apo ε3 were by far the most fre-pressed as the mean 
 standard deviation.
quent in all groups with nephrotic syndrome (69.9%),
followed by heterozygous ε3ε4 (15.8%), ε2ε3 (11%), ε2ε4RESULTS
(2.9%) and by homozygous ε4ε4 (0.5%) and ε2ε2 (0%).
ApoE genotypes All these frequencies were equally distributed among
Apolipoprotein E genotypes were determined in 209 the subgroups and were not different from controls.
nephrotic children (N  159) and adults (43) with a net
ApoE in serum and urineprevalence of FSGS (Table 1) and 127 normal controls.
Data on the apoE genotype of 398 normal Italian sub- Before starting the screening study on apoE levels in
serum and urine, we tested the specificity of antibodiesjects reported in another study [19] were utilized for
statistical purposes. These patients had been subdivided (Fig. 1) and validated the new assay for apoE determina-
tion based on dot-blot in a subgroup of patients. Theaccording to the responsiveness to steroids in corticosen-
sitive (N  37), corticodependent (33) and corticoresis- results showed a linearity of the assay in a range of apoE
levels between 0.1 and 50 g/mL (Fig. 2); the coefficienttant (139). The high number of patients with corticoresis-
tance and FSGS did not represent the effective incidence of variation was less than 2.5%.
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nephrotic range. All but three were receiving steroids at
the time of the enrollment, in some cases associated with
cyclosporine; most patients also were receiving statins.
Serum levels of apoE varied between 40 g/mL (that is,
upper limit in normal range) to almost 1000 g/mL.
However, due to the skewed incidence of elevated serum
apoE levels among the patients and to the minimal range
of variation in the normal population, the difference
between nephrotic patients and controls was highly sig-
nificant (44.6 
 2.9 g/mL controls vs. 261.9 
 222.5
nephrotic and 180.14
 188.7 FSGS, P0.001; Table 4).
Moreover, as it appears in the same table, serum apoE
was comparably high in a cohort of nephrotic patients
with a different form of nephropathy, such as MN (226.35

87), suggesting that the very high levels of apoE in serum
is more of a general characteristic of NS than a peculiar-
ity of a specific histopathological group. Looking at possi-
ble factors that may influence apoE serum levels in NS,
we considered other lipids. As shown in Figure 5, serum
apoE and cholesterol were directly correlated (P 
0.001), confirming our original hypothesis.
The urinary levels represented in all cases a 10,000th
fraction of serum (that is, in the range of ng/mL) with
significant differences between nephrotic subjects (0.088

Fig. 1. Specificity of anti-apolipoprotein E (anti-apoE) monoclonal an- 0.150 g/mL) and those with FSGS (0.02 
 0.06 g/mL)
tibodies was evaluated by two dimensional electrophoresis and immu-
versus controls (0.006
 0.002 g/mL). The characteriza-noblot of a normal serum. These antibodies recognized different glyco-
sylated isoforms of apoE. Abbreviations are: pI, isoelectric points; MW, tion of urinary apoE by two-dimensional electrophoresis
molecular weight. showed the same isoforms as in this serum, therefore
excluding a selective excretion.
Renal expression of apoE
Serum levels of apoE were first evaluated in a cross-
Renal expression of apoE was evaluated by indirectsection of 60 patients of the entire cohort to identify any
immunofluorescence in 12 FSGS patients and was com-possible correlation between apoE genotypes and levels.
pared to 6 MN and 10 normal kidneys. The results areSeveral serum samples were obtained from these pa-
illustrated in Figures 6 and 7, which reported an exampletients, at different stages unrelated to disease activity,
for every category. In all kidneys, apoE was mainly de-and were tested to document variability within the same
tected in blood vessels of the tubulointerstitium (Fig.genotype group. There was a random distribution of
6A) and in a few tubuli (Fig. 6B); less intense, albeitapoE levels in the groups presenting different genotypes
evident, staining was observed in normal glomeruli (Fig.
(Fig. 3). It is relevant that considering carriers of the
7A). Glomeruli from patients with MN stained even
ε3ε3, which is by far the most frequent haplotype, serum more intensely (Fig. 7C), particularly in the capillary
apoE varied from the normal range of 40 mg/L up to tuft. By contrast, in FSGS glomeruli (Fig. 7B) the apoE
very high levels of 600 to 800 mg/L. This excludes an staining was completely absent, this finding being con-
influence of genetic factors on serum apoE levels. At firmed in all biopsies.
the same time, a direct correlation between apoE levels
and proteinuria was observed in these patients (P 
DISCUSSION0.001; Fig. 4).
For 28 children, 20 with idiopathic nephrotic syndrome Cumulative data suggest an implication of apoE in
and 8 with FSGS, serum and urine were obtained at atherosclerosis and FSGS causing at least two separate
disease onset or during a relapse; frozen sections of the effects, one involving the apoE genotype and the other
kidney also were available in this group. The clinical apoE levels in serum and kidney. Genetically-engineered
characteristics of the 28 patients of this pilot study to- mice lacking apoE develop hypercholesterolemia and
gether with the results on apoE levels are reported in glomerulosclerosis [8, 9], this supporting the quantitative
Tables 2 and 4. All but two patients of the FSGS group decrease as a major effect of apoE in this setting. On the
other hand, homozygous carriers of the apo ε2 genotypehad normal renal function and all had proteinuria in the
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Fig. 2. Calibration curve of the dot-blot assay
obtained with a purified apoE standard and
with two normal sera at different dilutions.
The average optical densities for chemilumi-
nescence were plotted against the amount of
apoE. The concentration of the standard was
varied from 0.005 to 26 g/mL. (Insert) The
plot of a logarithmic base shows the sensitivity
at very low levels. Symbols are: () apoE; ()
serum 1; () serum 2; () serum 3.
Fig. 3. Random distribution of apoE serum levels with respect to the Fig. 4. Correlation between serum apoE and proteinuria in the cohort
genotype in 60 patients from whom a serum sample was obtained at of 60 patients from a whom more than one serum sample was obtained
different periods, unrelated from the levels of proteinuria. Serum apoE at different phases of the disease varying from mild to overt proteinuria
was variable within patients with the same apoE genotype. Also, those (P  0.001). y  a  bX, where a  0.621, b  0.017, and r  0.38.
patients who had more than one determination presented variable levels
despite the same genotype.
[23]. Accordingly, hypolipemic agents confer functional
and histologic protection [24–26], whereas the super-develop hypercholesterolemia and occasionally progres-
imposition of alimentary hypercholesterolemia worsenssive renal glomerular damage characterized by an abnor-
the outcome of experimental FSGS in rats [27]. In hu-mal accumulation of lipoproteins and foam cells [18].
mans, treatment of hyperlipemia with probucol or re-Pathological variants of apoE such as the Sendai and
moval of LDL by apheresis reduces proteinuria asso-others are associated also with the development of simi-
ciated with FSGS [9, 28]. The similarities betweenlar lesions [14–17], which supports the idea that genetic
atherosclerosis and FSGS have been addressed in thevariants of apoE may be implicated in FSGS. It is note-
past without reaching solid conclusions, but it is clearworthy that the histological features of FSGS include
that a pathogenetic role of a molecule that is implicatedthe accumulation of extracellular matrix and lipids in
in both conditions, such as apoE, is yet to be furtherlimited areas of glomeruli and, analogous to the role of
defined.lipids in atherosclerosis, glomerular lipid accumulation
has been implicated in the development of renal lesions Our data conclusively demonstrate that the predomi-
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Table 4. Serum and urinary levels of apolipoprotein E in 20 children
with idiopathic nephrotic syndrome (NS), 8 with focal segmental
glomerulosclerosis (FSGS), 22 with membranous nephropathy (MN)
and 50 normal controls
Serum ApoE Urinary ApoE
Patient Creatinine
number l/glg/mL
Controls 50 44.6
2.9 0.006
0.002 0.007
0.002
NS 20 261.9
222.5a 0.088
0.150a 1.173
0.2
FSGS 8 180.14
188.7b 0.020
0.060b 0.029
0.08
MN 22 226.35
87.64a 0.044
0.079a 0.055
0.098
Urinary apolipoprotein E levels refer to the morning micturation and are
expressed as g/mL.
aP  0.001
bP  0.001
Fig. 5. Correlation between serum apoE and cholesterol in 28 children
who presented nephrotic syndrome (), eight showing the histologicalnant genotype in nephrotic patients with corticorestance
picture of FSGS (). Fifty normal controls are represented by the open
is, by far, apo ε3, and that the presence of homozygous circles (; P  0.001). y  bX, where a  170.30, b  0.322, and r 
0.53.and heterozygous carriers of the ε2 genotype in a statisti-
cally informative population of children and adults with
FSGS is only occasional. These results exclude a relevance
of the apoE variants in this pathology. In this respect,
studied at different times. A relevant example is the widewe cannot confirm previous data of the literature on an
variability of serum apoE in carriers of the apo ε3ε3association of the apo ε2 and ε4 alleles with FSGS in two haplotype that present levels from the normal range upsmall cohorts of patients [11] and on a higher frequency
to 800 mg/L. On the other hand, in view of the strongof apo ε2 in a vast Japanese population with end-stage
correlation between apoE and serum cholesterol, werenal disease [13]. However, in this latter study only a
hypothesize that the same mechanism causing hypercho-small portion of patients presented proteinuria and no
lesterolemia and high LDL up-regulates apoE levels,clear indications of the basic disease were available.
and further studies should focus on this regulatory as-The second major finding of our study is that there
pect. The significance of high apoE in the context ofis a dysregulation of apoE in nephrotic syndrome that
the severe hyperlipemia that characterizes these patientsdetermines very high levels in serum and in urine, while
should be addressed further, since the hypocholestero-(at least in FSGS) the renal expression appears to be
lemic function of this apolipoprotein is well recognized.down-regulated. In fact, serum levels of apoE in NS is
On the other hand, we also found that urinary levels ofhigher than in normal serum by a factor of five, this
apoE increase in parallel with serum levels, reaching aincrement being correlated with hypercholesterolemia.
tenfold increment in nephrotic patients. By plotting se-Serum apoE levels were comparably high in a group
rum apoE and proteinuria a positive and high statisticalof nephrotic patients with MN, indicating that this is
correlation was found. This is in agreement with the ideaa characteristic of nephrotic syndrome more than of a
that apoE, which is a low molecular weight protein ofspecific clinical group. This is an unexpected finding since
about 30 kD, is not reabsorbed at the tubular level.apoE3, which is the most frequent variant found in our
The other aspect of apoE regulation in nephrotic syn-patients, is a component of HDL, whose levels in NS
drome is the low expression of apoE in glomeruli ofare unchanged or slightly decreased [3]. Obviously, we
affected patients and its complete absence in areas ofcannot exclude some pharmacological effects since al-
sclerosis. By comparison, apoE was found to be hyper-most all patients were receiving steroids. However, of
expressed in glomeruli of other nephrotic patients withthe three patients not receiving steroids at the enroll-
MN, suggesting that low glomerular apoE is a character-ment, two (patients 5 and 24) presented high apoE levels,
istic of FSGS. This is of particular interest, since withinthus suggesting that this parameter is not influenced by
the glomerulus apoE inhibits mesangial cell proliferationimmunosuppression. Following the initial observation on
and extracellular matrix expression, which are two mech-very high apoE levels, we sought for regulatory mecha-
anisms causing glomerulosclerosis. Actually, it is wellnisms and excluded a direct relationship with the geno-
known that, besides the liver, the kidney is a major sourcetype. In a cross section of the study population, several
of apoE synthesis [29, 30] and RT-PCR analysis of differ-serum samples were obtained at different times, irrespec-
ent kidney cell types showed that mesangial cells are ative of the disease activity, and the results on apoE levels
major source of apoE renal expression [7]. Mice deficientclearly document a random distribution among patients
with the same genotype and/or among the same subjects in apoE have both increased proliferation and matrix
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Fig. 6. ApoE expression in vascular struc-
tures of the tubulointerstitium (A ) and in tu-
bular cells (B) of a patient with nephrotic syn-
drome with minimal lesions.
Fig. 7. ApoE expression in glomeruli deriving from (A ) a normal kidney, (B ) a patient with FSGS and (C ) a patient with MN. These immunostainings
are examples of what observed in several biopsies with the different pathologies (12 with FSGS, 6 with MN and 10 normal kidneys).
overproduction, two hallmarks of glomerulosclerosis. ACKNOWLEDGMENTS
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